The development of therapeutic approaches that target BRCA-mutant tumours has led to the possibility of expanding the range of patients who may benefit from such strategies. Tumours with 'BRCAness', a similar phenotype to germline BRCA-mutant tumours, are increasingly being identified, and this Opinion article discusses the advances and challenges in this context.
- Christopher J. Lord
- Alan Ashworth